REGISTERED
on 10 Mar 2020
Last Applicant/ Owned by
1035 Cambridge Street
Cambridge
MA
02141
Serial Number
88028473 filed on 06th Jul 2018
Registration Number
6008690 registered on 10th Mar 2020
Correspondent Address
Rachelle A. Dubow, Esq.
Filing Basis
1. use application currently
Disclaimer
NO DATA
FACTOR BIOSCIENCE
Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of c Read More
Classification Information
Class [001]
Chemical Products
Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering
First Use Date in General
19th Nov 2019
First Use Date in Commerce
19th Nov 2019
Class [005]
Pharmaceutical Products
Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease
First Use Date in General
30th Sep 2011
First Use Date in Commerce
30th Sep 2011
Class [009]
Computer & Software Products & Electrical & Scientific Products
Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments
First Use Date in General
08th Nov 2019
First Use Date in Commerce
08th Nov 2019
Class [042]
Computer & Software Services & Scientific Services
Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing
First Use Date in General
30th Sep 2011
First Use Date in Commerce
30th Sep 2011
Mark Details
Serial Number
No 88028473
Mark Type
No Service Mark
Attorney Docket Number
No 107541-0038
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 10th Mar 2020 | REGISTERED-PRINCIPAL REGISTER |
| 05th Feb 2020 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 04th Feb 2020 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 29th Dec 2019 | STATEMENT OF USE PROCESSING COMPLETE |
| 29th Dec 2019 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 18th Dec 2019 | USE AMENDMENT FILED |
| 18th Dec 2019 | TEAS STATEMENT OF USE RECEIVED |
| 13th Aug 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 18th Jun 2019 | PUBLISHED FOR OPPOSITION |
| 18th Jun 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |